Enveric Biosciences Inc vs SAP SE — how do they compare? Enveric Biosciences Inc trades at $1.36 (market cap $5.32M), while SAP SE trades at $156.72 (market cap $182.13B). The key difference: SAP SE is far larger — about 34235× Enveric Biosciences Inc's market cap, and SAP SE pays a 1.88% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SAP | |
|---|---|---|
Market Cap | $5.32M | $182.13B |
Sector | Health | Technology |
52-Week High | $17.40 | $308.61 |
52-Week Low | $1.28 | $148.06 |
Enterprise Value | $408.82K | $179.64B |
Dividend Yield | — | 1.88% |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
No Aura AI signal available yet.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →